<DOC>
	<DOCNO>NCT00005873</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness nitrocamptothecin treat patient locally recurrent metastatic breast cancer .</brief_summary>
	<brief_title>Nitrocamptothecin Treating Patients With Locally Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess toxicity efficacy nitrocamptothecin patient locally recurrent metastatic breast cancer . II . Determine duration response time treatment failure patient treatment regimen . III . Correlate serum level nitrocamptothecin lactone metabolite response toxicity patient . IV . Correlate topoisomerase I II level toxicity response patient . OUTLINE : Patients receive oral nitrocamptothecin daily day 1-5 . Treatment continue weekly 8 week . Patients achieve complete partial response stable disease continue therapy absence disease progression unacceptable toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 18-43 patient accrue study within 8-18 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Rubitecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm locally recurrent metastatic breast cancer amenable surgery radiotherapy Measurable evaluable disease No prior radiotherapy target lesion Disease progression 2 prior chemotherapy treatment metastatic disease No active CNS metastasis Prior CNS metastasis allow evidence active disease Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : Not specify Menopausal status : Not specify Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute granulocyte count great 1,500/mm3 Hemoglobin great 9.0 g/dL Platelet count great 100,000/mm3 Hepatic : Bilirubin great 2.0 mg/dL AST/ALT great 3 time upper limit normal ( ULN ) ( great 5 time ULN case liver metastasis ) Renal : Creatinine great 2.0 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Must able daily fluid intake least 3 liter No concurrent active infection No prior malignancy past 5 year except adequately treat basal cell carcinoma skin carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No prior irinotecan , topotecan , camptothecin analogue At least 3 week since prior chemotherapy Endocrine therapy : No concurrent corticosteroid control CNS disease Radiotherapy : See Disease Characteristics At least 2 week since prior radiotherapy Surgery : At least 4 week since prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2001</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>